Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset fabry mutation (IVS4 + 919G > A)

Orphanet Journal of Rare Diseases

Volumn 9, Issue 1, 2014, Pages

  Hsu, Ting Rong ^a,b   Sung, Shih Hsien ^a   Chang, Fu Pang ^b   Yang, Chia Feng ^b   Liu, Hao Chuan ^b   Lin, Hsiang Yu ^c   Huang, Chun Kai ^b,d   Gao, He Jin ^b,d   Huang, Yu Hsiu ^b,d   Liao, Hsuan Chieh ^e   Lee, Pi Chang ^b   Yang, An Hang ^b   Chiang, Chuan Chi ^e   Lin, Ching Yuang ^f   Yu, Wen Chung ^a   Niu, Dau Ming ^a,b,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d Taiwan Clinical Trial Consortium in Fabry Disease   (Taiwan)

^e Chinese Foundation of Health   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Endomyocardial biopsy; Enzyme replacement therapy; Fabry disease; Left ventricular hypertrophy

Indexed keywords

BIOPSY; CARDIAC MUSCLE; CHINA; FABRY DISEASE; FEMALE; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; ADULT; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CARDIOVASCULAR MAGNETIC RESONANCE; CHINESE; CLINICAL ARTICLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; ENZYME REPLACEMENT; GENE MUTATION; HEART MUSCLE BIOPSY; HUMAN TISSUE; RETROSPECTIVE STUDY;

BIOPSY; CHINA; FABRY DISEASE; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; MUTATION; MYOCARDIUM;

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; ANTIHYPERTENSIVE AGENT; GLOBOTRIAOSYLCERAMIDE;

EID: 84904413352     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-9-96     Document Type: Article

References (67)

1. Prevalence of lysosomal storage disorders. Meikle PJ, Hopwood JJ, Clague AE, Carey WF, JAMA 1999 281 249 254 (Pubitemid 29058114)
2. Fabry disease: clinical features and recent advances in enzyme replacement therapy. Desnick RJ, Wasserstein MP, Adv Nephrol Necker Hosp 2001 31 317 339
3. Fabry disease in childhood. Desnick RJ, Brady RO, J Pediatr 2004 144 20 S26
4. Fabry's disease. Zarate YA, Hopkin RJ, Lancet 2008 372 1427 1435
5. Cardiac challenges in patients with Fabry disease. Weidemann F, Linhart A, Monserrat L, Strotmann J, Int J Cardiol 2010 141 3 10
6. Severe left ventricular hypertrophy in Anderson-Fabry disease. Bhatia GS, Leahy JF, Connolly DL, Davis RC, Heart 2004 90 1136 (Pubitemid 39279896)
7. Treatment of Anderson-Fabry disease. Linhart A, Heart 2008 94 138 139 (Pubitemid 351211716)
8. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Kampmann C, Linhart A, Baehner F, Palecek T, Wiethoff CM, Miebach E, Whybra C, Gal A, Bultas J, Beck M, Int J Cardiol 2008 130 367 373
9. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M, Heart 2009 95 1103 1107
10. Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. Monserrat L, Gimeno-Blanes JR, Marin F, Hermida-Prieto M, Garcia-Honrubia A, Perez I, Fernandez X, de Nicolas R, de la Morena G, Paya E, Yague J, Egido J, J Am Coll Cardiol 2007 50 2399 2403 (Pubitemid 50011583)
11. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, Yoshida A, Kuriyama M, Hayashibe H, Sakuraba H, Tanaka H, N Engl J Med 1995 333 288 293
12. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM, Circulation 2002 105 1407 1411 (Pubitemid 34263268)
13. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Fodinger M, Sunder-Plassmann G, J Am Soc Nephrol 2004 15 1323 1329 (Pubitemid 38526014)
14. Recurrent strokes in a young adult patient with Fabry's disease. Tanaka N, Utsumi K, Seta T, Usuda K, Komaba Y, Katsumata T, Katsura KI, Sakamoto S, Katayama Y, Eur J Neurol 2005 12 486 487 (Pubitemid 40768671)
15. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome. Nance CS, Klein CJ, Banikazemi M, Dikman SH, Phelps RG, McArthur JC, Rodriguez M, Desnick RJ, Arch Neurol 2006 63 453 457
16. Fabry disease. Nagueh SF, Heart 2003 89 819 820 (Pubitemid 36920791)
17. High incidence of cardiac variant of fabry disease in Taiwanese revealed by newborn screening. Chong KW, Lu YH, Hsu JH, Lo MY, Hsiao CY, Niu DM, Taiwan Hum Genet Soc Autumn Symp 2008 1 92 98
18. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. Lin HY, Chong KW, Hsu JH, Yu HC, Shih CC, Huang CH, Lin SJ, Chen CH, Chiang CC, Ho HJ, Lee PC, Kao CH, Cheng KH, Hsueh C, Niu DM, Circ Cardiovasc Genet 2009 2 450 456
19. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 + 919G > A (IVS4 + 919G > A). Hwu WL, Chien YH, Lee NC, Chiang SC, Dobrovolny R, Huang AC, Yeh HY, Chao MC, Lin SJ, Kitagawa T, Desnick RJ, Hsu LW, Hum Mutat 2009 30 1397 1405
20. Fabry disease: incidence of the common later-onset -galactosidase A IVS4+919G→A mutation in Taiwanese newborns-superiority of DNA-based to enzyme-based newborn screening for common mutations. Chien YH, Lee NC, Chiang SC, Desnick RJ, Hwu WL, Mol Med 2012 18 780 784
21. Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G > A). Lin HY, Liu HC, Huang YH, Liao HC, Hsu TR, Shen CI, Li ST, Li CF, Lee LH, Lee PC, Huang CK, Chiang CC, Lin CY, Lin SP, Niu DM, BMJ Open 2013 3 003146 doi:10.1136/bmjopen-2013-003146
22. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G- > A). Lin HY, Huang CH, Yu HC, Chong KW, Hsu JH, Lee PC, Cheng KH, Chiang CC, Ho HJ, Lin SP, Chen SJ, Lin PK, Niu DM, J Inherit Metab Dis 2010 33 619 624
23. Evaluation of recombinant alpha-galactosidase A therapy for amelioration of the cardiovascular manifestations of Fabry disease: an important role for endomyocardial biopsy. Buja LM, Circulation 2009 119 2539 2541
24. The use of high resolution melting analysis to detect Fabry mutations in heterozygous females via dry bloodspots. Tai CL, Liu MY, Yu HC, Chiang CC, Chiang H, Suen JH, Kao SM, Huang YH, Wu TJ, Yang CF, Tsai FC, Lin CY, Chang JG, Chen HD, Niu DM, Clin Chim Acta 2012 413 422 427
25. High-throughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry. Lee SH, Li CF, Lin HY, Lin CH, Liu HC, Tsai SF, Niu DM, Mol Genet Metab 2014 111 507 512
26. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease: mutations in brief no. 169: online. Chen CH, Shyu PW, Wu SJ, Sheu SS, Desnick RJ, Hsiao KJ, Hum Mutat 1998 11 328 330 (Pubitemid 28177875)
27. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, Kuiper S, Bergh V, Weerman MA, Groener JE, Poorthuis BJ, Hollak CE, Aerts JM, Biochim Biophys Acta 1802 2010 741 748
28. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ, Proc Natl Acad Sci U S A 2008 105 2812 2817 (Pubitemid 351723626)
29. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4 + 919G > A). Liao HC, Huang YH, Chen YJ, Kao SM, Lin HY, Huang CK, Liu HC, Hsu TR, Lin SP, Yang CF, Fann CS, Chiu PC, Hsieh KS, Fu YC, Ke YY, Lin CY, Tsai FJ, Wang CH, Chao MC, Yu WC, Chiang CC, Niu DM, Clin Chim Acta 2013 426 114 120
30. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N, Am J Cardiol 1986 57 450 458 (Pubitemid 16119719)
31. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS, Investigators C, Hypertension 2002 40 41 46 (Pubitemid 34755977)
32. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Foppa M, Duncan BB, Rohde LE, Cardiovasc Ultrasound 2005 3 17
33. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Beer M, Weidemann F, Breunig F, Knoll A, Koeppe S, Machann W, Hahn D, Wanner C, Strotmann J, Sandstede J, Am J Cardiol 2006 97 1515 1518
34. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Stork S, Voelker W, Ertl G, Wanner C, Strotmann J, Circulation 2009 119 524 529
35. Concentric hypertrophic remodelling and subendocardial dysfunction in mitochondrial DNA point mutation carriers. Bates MG, Hollingsworth KG, Newman JH, Jakovljevic DG, Blamire AM, Macgowan GA, Keavney BD, Chinnery PF, Turnbull DM, Taylor RW, Trenell MI, Gorman GS, Eur Heart J Cardiovasc Imaging 2013 14 650 658
36. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS, Circulation 2002 105 539 542 (Pubitemid 34262671)
37. Histologically measured cardiomyocyte hypertrophy correlates with body height as strongly as with body mass index. Tracy RE, Sander GE, Cardiol Res Pract 2011 2011 658958
38. Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease. Chimenti C, Hamdani N, Boontje NM, DeCobelli F, Esposito A, Bronzwaer JG, Stienen GJ, Russo MA, Paulus WJ, Frustaci A, van der Velden J, Am J Pathol 2008 172 1482 1490 (Pubitemid 351793342)
39. Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study. Chimenti C, Padua L, Pazzaglia C, Morgante E, Centurion C, Antuzzi D, Russo MA, Frustaci A, Hum Pathol 2012 43 1444 1452
40. Cardiomyocyte size estimated from noninvasive measurements of left ventricular wall thickness and chamber diameter. Tracy RE, J Am Soc Hypertens 2012 6 185 192
41. Eccentric may differ from concentric left ventricular hypertrophy because of variations in cardiomyocyte numbers. Tracy RE, J Card Fail 2013 19 517 522
42. High incidence of later-onset fabry disease revealed by newborn screening. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, Ponzone A, Desnick RJ, Am J Hum Genet 2006 79 31 40 (Pubitemid 43927374)
43. Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study. Inoue T, Hattori K, Ihara K, Ishii A, Nakamura K, Hirose S, J Hum Genet 2013 58 548 552
44. Fabry disease: biochemical, pathological and structural studies of the alpha-galactosidase A with E66Q amino acid substitution. Togawa T, Tsukimura T, Kodama T, Tanaka T, Kawashima I, Saito S, Ohno K, Fukushige T, Kanekura T, Satomura A, Kang DH, Lee BH, Yoo HW, Doi K, Noiri E, Sakuraba H, Mol Genet Metab 2012 105 615 620
45. Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry. Kitagawa T, Ishige N, Suzuki K, Owada M, Ohashi T, Kobayashi M, Eto Y, Tanaka A, Mills K, Winchester B, Keutzer J, Mol Genet Metab 2005 85 196 202 (Pubitemid 40840759)
46. Mutant alpha-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level. Mitobe S, Togawa T, Tsukimura T, Kodama T, Tanaka T, Doi K, Noiri E, Akai Y, Saito Y, Yoshino M, Takenaka T, Saito S, Ohno K, Sakuraba H, Mol Genet Metab 2012 107 623 626
47. Sequelae of storage in Fabry disease-pathology and comparison with other lysosomal storage diseases. Elleder M, Acta Paediatr Suppl 2003 92 46 53 discussion 45 (Pubitemid 38134751)
48. Light- and electron-microscopic histochemistry of Fabry's disease. Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop DF, Schuchman E, Desnick RJ, Am J Pathol 1981 103 247 262 (Pubitemid 11112979)
49. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Hoffmann B, Orphanet J Rare Dis 2009 4 21
50. Anderson-Fabry disease: a multiorgan disease. Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G, Curr Pharm Des 2013 19 5974 5996
51. Fabry disease. Germain DP, Orphanet J Rare Dis 2010 5 30
52. Fabry disease: a morphologic study of 11 cases. Fischer EG, Moore MJ, Lager DJ, Mod Pathol 2006 19 1295 1301 (Pubitemid 44423075)
53. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, N Engl J Med 2001 345 9 16 (Pubitemid 32634266)
54. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Thurberg BL, Fallon JT, Mitchell R, Aretz T, Gordon RE, O'Callaghan MW, Circulation 2009 119 2561 2567
55. An atypical variant of Fabry's disease with manifestations confined to the myocardium. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ, N Engl J Med 1991 324 395 399
56. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M, Eng CM, Desnick RJ, N Engl J Med 2001 345 25 32 (Pubitemid 32634268)
57. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, Yoshida H, Horinouchi M, Tabata K, Yonezawa S, Highchi K, Nakao S, Anan R, Minagoe S, Tei C, J Cardiol 2008 51 50 59 (Pubitemid 351699928)
58. Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Germain DP, Shabbeer J, Cotigny S, Desnick RJ, Mol Med 2002 8 306 312
59. Autonomic nervous system activity in patients with Fabry disease. Eric A, Aurore S, R F, Vincent P, Jean-Claude B, Open J Intern Med 2012 2 116 122
60. Targeted sequencing of over 4000 hypertrophic cardiomyopathy (HCM) patients for mutations causing HCM and Fabry disease: HCM mutations frequent n patients with GLA later0onset mutations, polymorphisms, and variant. Desnick RJ, Doheny D, Mol Genet Adn Metab 2014 111 36 s37
61. Galactosidase a deficiency: Fabry disease (2001). Desnick RJ, Ioannou YA, Eng CM, Metab Mol Bases Inherited Dis 2001 8th edn 3373 3774
62. Raised HDL cholesterol in Fabry disease: response to enzyme replacement therapy. Cartwright DJ, Cole AL, Cousins AJ, Lee PJ, J Inherit Metab Dis 2004 27 791 793 (Pubitemid 39433611)
63. Effect of selective LDL-apheresis in a Fabry patient with recurrent strokes. Utsumi K, Seta T, Katsumata T, Komaba Y, Igarashi H, Katsura KI, Iino Y, Katayama Y, Eur J Neurol 2006 13 429 430
64. Agalsidase benefits renal histology in young patients with Fabry disease. Tondel C, Bostad L, Larsen KK, Hirth A, Vikse BE, Houge G, Svarstad E, J Am Soc Nephrol 2013 24 137 148
65. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Weidemann F, Breunig F, Beer M, Sandstede J, Stork S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann JM, Eur Heart J 2005 26 1221 1227 (Pubitemid 40863129)
66. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC, Circ Cardiovasc Imaging 2013 6 392 398
67. MR-based analysis of regional cardiac function in relation to cellular integrity in Fabry disease. Koeppe S, Neubauer H, Breunig F, Weidemann F, Wanner C, Sandstede J, Machann W, Hahn D, Kostler H, Beer M, Int J Cardiol 2012 160 53 58